In Situ Liposomal Preparation Containing Amphotericin B: Related Toxicity and Tissue Disposition Studies

REFERENCES

• Lee J. W., Amantea M. A., Franchis P. A., Navarro E. E., Bacher J., Pizzo P. A., Walsh T. J. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 1997; 38(4)713–718
   Google Scholar
• Rapp R. P., Gubbins P. O., Evans M. E. Amphotericin B lipid complex. Ann. Pharmacother. 1997; 31: 1174–1186
   PubMedGoogle Scholar
• Gabizon A., Martin F. Polyethylene glycol-coated (Pegylated) liposomal doxorubicin. Drugs 1997; 54(suppl. 4)15–21
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposome encapsulation: Comparison of normal mice infected with Candida albicans. Cancer Drug Delivery 1984; 1: 199–205
   PubMedGoogle Scholar
• Tremblay C., Barza M., Fiore C., Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 1984; 26: 170–173
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Grant C. M. W., Barber K. R., Kalp A. Mechanism of selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 1986; 31: 1–11
   Web of Science ®Google Scholar
• Perrett S., Golding M., Williams W. P. A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J. Pharm. Pharmacol. 1991; 43: 154–161
   PubMed Web of Science ®Google Scholar
• Gregoriadis G., McCormeck B. PCT Int. Appl., 44 pp., 1995. Patent specification WO 9515746A1, Cyclodextrin News, 1995, 10(8) 132
   Google Scholar
• Irie T., Uckama K. Pharmaceutical application of cyclodextrin (III)—Toxicological issues and safety evaluation. J. Pharm. Sci. 1997; 86(2)147–162
   PubMed Web of Science ®Google Scholar
• Surolia A., Bachhawat B. K., Podder S. K. Interaction between lectin from ricinus communis and liposomes containing gangliosides. Nature 1975; 257: 802–804
   PubMed Web of Science ®Google Scholar
• Adhage N. A., Vavia P. R. Grinding: A method for β-cyclodextrin inclusion complexation. 17th Asian Congress of Pharmaceutical Sciences, Mumbai (Bombay)India, December, 10–131998, 25, Abstract IA12
   Google Scholar
• Giron D. J. Swarbic, J. C. BoylanThermal analysis of drugs and drug products. Encyclopedia of Pharmaceutical Technology, . Marcel Dekker, Inc., New York 1997; 15: 56–58
   Google Scholar
• Uckama K., Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 1987; 38: 189–193
   Google Scholar
• Hayert M. A. Principles and Techniques of Electron Microscopy. Van Nostrand Reinhold, New York 1970
   Google Scholar
• Vaskovsky V. E., Kostetsky E. Y., Vasendin I. M. A universal reagent for phospholipid analysis. J. Chromatogr. 1975; 114: 129–141
   PubMed Web of Science ®Google Scholar
• Litchfield J. T., Wilcoxon F. A., Jr. Simplified method of evaluating dose effects experiments. J. Pharmacol. Exp. Ther. 1949; 96: 99–113
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle I., Yoshikawa T. T., Edwards J. E., Schotzand M. C., Guze L. B. Quantitation of amphotericin B with use of high-pressure liquid chromatography. J. Infect. Dis. 1977; 135: 414–422
   PubMedGoogle Scholar
• Ahmad I., Sarkar A. K., Bachhawat B. K. Liposomal amphotericin B in the control of experimental aspergillosis in mice: Part I—Relative therapeutic efficacy of free and liposomal amphotericin B. Indian J. Biochem. Biophys. 1989; 26: 351–356
   PubMed Web of Science ®Google Scholar
• Harindran J., Chakraborty K. K., Naik S. R. Preparation, relative toxicity and therapeutic efficacy of liposomal HA-1-92 (A new oxohexaene polyene macrolide antibiotic). J. Pharm. Pharmacol. 1999; 51: 771–776
   PubMed Web of Science ®Google Scholar
• Snedecor G. W., Cochran W. G. Statistical Methods. Oxford & IBH Publ. Co., India 1968; 227–279
   Google Scholar
• Fisher B. D., Armstrong B. Vn. D., Gold J. W. M. Invasive aspergillosis—progress in early diagnosis and treatment. Am. J. Med. 1981; 71: 571
   PubMed Web of Science ®Google Scholar
• Chakraborty K. K., Naik S. R. Pharmacokinetic analysis of in-situ liposomal preparation derived from proliposome. Symposium on Natural Origin Substances in Drug Formulation, BeijingChina, November, 4–61998, 39–40, Abstract PO2
   Google Scholar
• Tinker D. O., Saunders L. Studies of isotropic phosphotidylcholine-n-propanol-water system. Chem. Phys. Lipids 1968; 2: 316–329
   Google Scholar
• Chakraborty K. K., Naik S. R. Cryoprotection and drug leakage of in-situ liposomal preparations. National Symposium on Mycoses, DelhiIndia, May, 5–71997, 90, Abstract 26
   Google Scholar
• McCormack B., Gregoriadis G. Comparative studies of the fate of free and liposome-entrapped hydroxypropyl β-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. Biochim. Biophys. Acta 1996; 1291: 237–244
   PubMed Web of Science ®Google Scholar
• Duchene D., Wouessidjewe D., Poolman M. C. D. DucheneNew Trends in Cyclodextrin and Derivatives, . Editions de Sante, Paris 1991; 447–481
   Google Scholar
• Gerloczy A., Antal S., Szatmari I., Muller-Horvath R., Szetli J. D. DucheneMins. 5th International Symposium on Cyclodextrin, . Editions de Sante, Paris 1990; 507–513
   Google Scholar
• Joly V., Dromer F., Barge J., Yeni P., Seta M., Molas G., Carbon C. Incorporation of amphotericin B (AmB) into liposomes alters AmB induced acute nephrotoxicity in rabbits. J. Pharmacol. Exp. Ther. 1989; 251: 311
   PubMed Web of Science ®Google Scholar